EPI-FEM-CARE

EPIGENETICS FOR FEMALE PERSONALIZED CANCER CARE

 Coordinatore UNIVERSITY COLLEGE LONDON 

 Organization address address: GOWER STREET
city: LONDON
postcode: WC1E 6BT

contact info
Titolo: Ms.
Nome: Greta
Cognome: Borg-Carbott
Email: send email
Telefono: +44 20 3108 3033
Fax: +44 20 783 2849

 Nazionalità Coordinatore United Kingdom [UK]
 Totale costo 7˙649˙836 €
 EC contributo 5˙875˙387 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2012-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2012
 Periodo (anno-mese-giorno) 2012-11-01   -   2016-04-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE LONDON

 Organization address address: GOWER STREET
city: LONDON
postcode: WC1E 6BT

contact info
Titolo: Ms.
Nome: Greta
Cognome: Borg-Carbott
Email: send email
Telefono: +44 20 3108 3033
Fax: +44 20 783 2849

UK (LONDON) coordinator 2˙432˙712.00
2    GATC BIOTECH AG

 Organization address address: JAKOB STADLER PLATZ 7
city: KONSTANZ
postcode: 78467

contact info
Titolo: Dr.
Nome: Janet
Cognome: Kenklies
Email: send email
Telefono: +49 7531 816 0751
Fax: +49 7531 816081

DE (KONSTANZ) participant 1˙706˙106.00
3    GENEDATA AG

 Organization address address: MARGARETHENSTRASSE 38
city: BASEL
postcode: 4053

contact info
Titolo: Dr.
Nome: Timo
Cognome: Wittenberger
Email: send email
Telefono: +41 61 511 8443

CH (BASEL) participant 852˙245.00
4    EURAM LIMITED

 Organization address address: "Tower House, Lucy Tower Street"
city: LINCOLN
postcode: LN1 1XW

contact info
Titolo: Mr.
Nome: Andrew
Cognome: Banasik
Email: send email
Telefono: +44 1159 811335
Fax: +44 1159 541295

UK (LINCOLN) participant 354˙344.00
5    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

 Organization address address: GESCHWISTER SCHOLL PLATZ 1
city: MUENCHEN
postcode: 80539

contact info
Titolo: Dr.
Nome: Brigitte
Cognome: Rack
Email: send email
Telefono: 498952000000
Fax: 498952000000

DE (MUENCHEN) participant 299˙932.00
6    UNIVERZITA KARLOVA V PRAZE

 Organization address address: Ovocny trh 5
city: PRAHA 1
postcode: 11636

contact info
Titolo: Ms.
Nome: Kristyna
Cognome: Matejkova
Email: send email
Telefono: +420 224 964 264
Fax: +420 224 964 163

CZ (PRAHA 1) participant 230˙048.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

trial    related    industrial    ovarian    breast    disease    women    cohort    cancer    stratification    personalised    clinical    screening    treatment    epifemcare    patients    dna    tests    reduce   

 Obiettivo del progetto (Objective)

'CLINICAL NEED Every year in the EU ~45,300 and 330,000 women are diagnosed with ovarian and breast cancer respectively & 28,800 and 90,000 of these two groups of women will die as a consequence of these diseases. Currently there are no tools available that allow for: a) Effective screening of ovarian and/or breast cancer of sufficient sensitivity and specificity to avoid potential over-diagnosis, or; b) Stratification of patients into optimal personalised therapy regimes in ovarian/breast cancer.

EpiFemCare ADVANCES Progress in personalised cancer medicine will only be possible with the development of bioassays involving the analysis of easy accessible biomaterials that contain stable target molecules reflective of disease. We will establish and clinically validate a series of blood tests based upon DNA methylation technology that will facilitate both early detection and prediction of therapeutic outcome in breast and ovarian cancer.

CONSORTIUM Our pan-European academic-industrial consortium demonstrates diverse clinical, scientific & industrial expertise. We have access to the latest state of the art technologies and, integrally, the best available cohort and clinical trial sample sets required to ensure the success of the EpiFemCare program. GATC-Biotech and Genedata are Europe’s leading providers of DNA sequencing and bioinformatics for biomarker development and have developed serum DNA based prenatal tests. The clinical partners have access to unique cohort and clinical samples collected from >200,000 women well in advance of disease (UK Collaborative Trial of Ovarian Cancer Screening) or before and during treatment (SUCCESS Trial).

IMPACT As a result of refined and improved patient stratification, EpiFemCare will: - Reduce the late stage presentation of ovarian & breast cancer by 50% - Reduce the requirement for 50% of breast cancer patients to have adjuvant therapies - Reduce female cancer related fatalities as well as treatment-related morbidity by 20%'

Altri progetti dello stesso programma (FP7-HEALTH)

DENFREE (2012)

Dengue research Framework for Resisting Epidemics in Europe

Read More  

GAMEXP (2009)

"Genomic approaches to metabolite exploitation from Xenorhabdus, Photorhabdus"

Read More  

NEO-CIRC (2011)

Dobutamine for NEOnatal CIRCulatory failure defined by novel biomarkers

Read More